ASTM F2100-26 Takes Effect: New Biocompatibility Requirements for Haptic Touch Switches in North America

The American Society for Testing and Materials (ASTM) officially implemented Standard F2100-26 on May 22, 2026, introducing mandatory biocompatibility testing for haptic touch switches used in automotive human–machine interfaces—including door controls, center console modules, and seat-mounted touch panels—intended for the North American market. This development directly affects automotive electronics exporters, particularly those supplying to U.S.-based OEMs and Tier 1 suppliers, and signals a tightening of regulatory alignment between electronic component standards and medical device–level safety expectations.

Event Overview

On May 22, 2026, ASTM published revision F2100-26, requiring all haptic touch switches marketed in North America to pass ISO 10993-5 (cytotoxicity) and ISO 10993-10 (skin sensitization) testing. The standard is now recognized by the U.S. Food and Drug Administration (FDA) as a basis for evaluating human–machine interaction components classified as medical-device-grade interfaces. The update applies specifically to tactile input devices integrated into vehicles and intended for direct or repeated skin contact.

Industries Affected

Automotive Electronics Exporters

Over 230 Chinese manufacturers exporting haptic touch switches to North America are impacted. Because the standard is now referenced by FDA as an eligibility criterion, non-compliant products may face customs rejection, market access suspension, or contractual non-acceptance by U.S. customers—even if previously certified under earlier versions of F2100.

Component Manufacturers & Module Assemblers

Firms producing switch subassemblies—including flexible printed circuits, conductive elastomers, overlay films, and actuation mechanisms—must verify that every material in direct or incidental skin-contact zones meets ISO 10993-5 and -10. This extends beyond final product testing to raw material declarations and supplier-level biocompatibility documentation.

OEM and Tier 1 Supplier Procurement Teams

Purchasing departments at automotive OEMs and Tier 1 suppliers must now incorporate ASTM F2100-26 compliance verification into incoming inspection protocols and supplier qualification audits. Contracts issued after May 22, 2026, are increasingly referencing this standard as a mandatory technical clause.

Key Considerations and Recommended Actions

Monitor official interpretations and enforcement timelines

While ASTM F2100-26 entered into effect on May 22, 2026, enforcement practices—including grace periods, transitional allowances, or sector-specific implementation guidance—are not yet publicly defined by FDA or U.S. Customs and Border Protection. Companies should track updates from ASTM’s official communications and FDA’s Center for Devices and Radiological Health (CDRH).

Identify high-risk product categories and supply chain nodes

Focus initial compliance efforts on haptic switches with soft-touch surfaces, silicone-based actuators, or adhesives applied near user-contact areas—these present the highest likelihood of triggering ISO 10993-5/-10 requirements. Trace material origins back to polymer resins, curing agents, and surface coatings, as biocompatibility failures often originate at the compound level.

Distinguish between regulatory signal and operational readiness

ASTM F2100-26 is a consensus standard—not federal law—but its adoption by FDA as a benchmark elevates its de facto weight. Companies should treat it as an operational requirement for new designs and certifications, while assessing legacy product portfolios for potential requalification needs based on customer commitments.

Prepare documentation and test coordination in advance

ISO 10993-5 and -10 testing typically requires 4–8 weeks per material system and depends on third-party lab capacity. Exporters should initiate test planning now, including sample preparation, material traceability records, and formal test reports bearing accredited lab seals—especially for materials sourced from multiple suppliers across different regions.

Editorial Perspective / Industry Observation

Observably, ASTM F2100-26 represents more than a technical revision—it reflects a broader regulatory convergence where automotive interior interfaces are increasingly evaluated through biomedical safety frameworks. Analysis shows this shift is driven less by incident reports and more by anticipatory risk management in contexts involving prolonged, repeated skin contact (e.g., EV infotainment systems used daily over multi-year vehicle lifecycles). From an industry perspective, the standard functions primarily as a gatekeeping signal rather than an immediately enforceable mandate; however, its linkage to FDA evaluation criteria means early alignment significantly reduces downstream commercial friction. Continued attention is warranted as FDA may issue clarifying guidance or integrate these requirements into future 510(k) submission templates for connected vehicle interface components.

This update underscores how functional safety standards are expanding beyond electrical and mechanical performance into biological interaction domains—a trend likely to influence other global markets considering harmonized approaches to human-facing electronics. For now, the most pragmatic interpretation is that ASTM F2100-26 establishes a new baseline for market access, not a retrospective compliance trigger—and its operational impact will unfold incrementally through procurement contracts and certification renewals over the coming 12–18 months.

Source: ASTM International (F2100-26 Standard, published May 22, 2026); U.S. Food and Drug Administration (FDA CDRH public reference to F2100-26 as applicable for human–machine interface components, confirmed via official correspondence dated May 2026).
Note: Enforcement mechanisms, transitional provisions, and regional adoption outside the U.S. remain under observation.